Discontinuation of protease inhibitors due to intolerance: A longitudinal study in 309 HIV-1 positive patients;Les arrets pour intolerance des traitements par inhibiteurs de la protease du VIH-1: Etude longitudinale de 309 patients

Presse Medicale

Volumn 28, Issue 8, 1999, Pages 381-387

  Piroth, L ^b   Grappin, M ^b   Waldner, A ^b   Sgro, C ^b   Duong, M ^b   Buisson, M ^b   Chavanet, P ^a   Portier, H ^b  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; KIDNEY FAILURE; STONE FORMATION; TREATMENT FAILURE; CLINICAL TRIAL; DRUG EFFECT; DRUG RESISTANCE; FEMALE; LONGITUDINAL STUDY; MALE; MIDDLE AGED;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INDINAVIR; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROTEASE INHIBITORS;

EID: 0033608322     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Mouton Y, Alfandari S, Valette M et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997 ; 11:F101-5.
2. Palella F, Delaney K, Moorman A et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998 ; 338:853-60.
3. Deeks S, Smith M, Holodniy M, Kahn J. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997 ; 277:145-53.
4. Katzenstein D. Adherence as a particular issue with protease inhibitors. J Assoc Nurses AIDS Care 1997 ; 8:S10-17.
5. Eldred L, Wu A, Chaisson R, Moore R. Adherence to antiretroviral and pneumocystis prophylaxis n HIV disease. JAIDS 1998 ; 18:117-25.
6. Casado J, Perez-Elias M, Antela A et al. Risk factors for ritonavir intolerance and outcome after change to indinavir. AIDS 1998 ; 12:335-6.
7. Stein D, Fish D, Bilello J, Preston S, Martineau G, Drusano G. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639. AIDS 1996 ; 16:485-92.
8. Hammer S, Squires K, Hughes M et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J of Med 1997 ; 337:725-33.
9. Gulick R, Mellors J, Havlir D et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997 ; 337:734-9.
10. Lewis J, Terriff C, Coulston D, Garrison M. Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus. Clin Ther 1997 ; 19:187-214.
11. Cameron D, Heath-Chiozzi M, Danner S et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998 ; 351:543-9.
12. Mc Donald C, Kuritzkes D. Human immunodeficiency virus type 1 protease inhibitors. Arch Intern Med 1997 ; 157:951-9.
13. Flexner C. HIV-protease inhibitors. N Engl J Med 1998 ; 338:1281-92.
14. Danner S, Carr A, Leonard J. A short term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. Clin Ther 1995 ; 19:299-315.
15. Markowitz M, Saag M, Powderly W. A preliminary study of ritonavir, an inhibitor of HIV-1 protease to treat HIV-1 infection. N Engl J Med 1995 ; 333:1534-9.
16. Sutnerland S, Reigle M, Seftel A, Resnick M. Protease inhibitors and urolithiasis. J Urol 1997 ; 158:31-3.
17. Daudon M, Estepa L, Viard J, Joly D, Jungers P. Urinary stones in HIV-1 positive patients treated with indinavir. Lancet 1997 ; 349:1294-5.
18. Beach J. Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions. Clin Ther 1998 ; 20:2-25.
19. Kopp J, Miller K, Mican J et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997 ; 127:119-25.
20. Hermieu J, Prévot M, Ravery V et al. Coliques néphrétiques sous indinavir. Presse Med 1998 ; 27:465-7
21. Lea A, Faulds D. Ritonavir. Drugs 1996 ; 52:541-6.
22. Hélal A. HIV protease inhibitors and increased bleeding in hemophilia. Can Med Assoc J 1997 ; 156:90.
23. Duong M, Sgro C, Grappin M, Biron F, Boibieux A. Renal failure after treatment with ritonavir. Lancet 1996 ; 348:693-4.
24. Chugh S, Bird R, Alexander E. Ritonavir and renal failure. N Engl J Med 1997 ; 336:138.
25. Rietsema W. Fever, erythroderma, abdominal pain, and renal failure following initiation of indinavir therapy. Clin Infect Dis 1997 ; 25:1268-9.
26. Sarcletti M, Petter A, Zangerle R. Indinavir and interstitial nephritis. Ann Intern Med 1998 ; 128:320.
27. Tashima K, Horowitz J, Rosen S. Indinavir nephropathy. N Engl J Med 1997 ; 336:138-140.
28. Chen S, Nankivell B, Dwyer D. Indinavir-induced renal failure. AIDS 1998 ; 12:441-2.
29. Von Moltke L. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 1998 ; 38:106-11.
30. Vento S. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. AIDS 1998 ; 12:116-7.
31. Eastone J, Decker C. New-onset diabetes mellitus associated with use of protease inhibitor. Inn Intern Med 1997 ; 127:948.
32. Visnegarwala F, Krause K, Musher D. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med 1997 ; 127:947.
33. Carr A, Samaras K, Burton S et al. A syndome of peripheral lipoystrophy, hyperlipidaemia and insulin resistance in patietns receiving HIV protease inhibitors. AIDS 1998 ; 12:F51-F8.
34. Wurtz R. Abnormal fat distribution and use of protease inhibitors. Lancet 1998 ; 351:1735-6.
35. Hengel R, Watts N, Lennox J. Benign symetric lipomatosis associated with protease inhibitors. Lancet 1997 ; 350:1596.
36. Miller K, Jones E, Yanovski J, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998 ; 351:871-5.
37. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998 ; 12:F37-9.